Metabolic features of clear-cell renal cell carcinoma: Mechanisms and clinical implications

Journal of the Canadian Urological Association

Volumn 5, Issue 4, 2011, Pages 274-282

  Pinthus, Jehonathan H ^a   Whelan, Kaitlyn F ^a   Gallino, Daniel ^a   Lu, Jian Ping ^a   Rothschild, Nathan ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79961201009     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.10196     Document Type: Review

References (75)

1. Rosner I, Bratslavsky G, Pinto PA, et al. The clinical implications of the genetics of renal cell carcinoma. Urol Oncol 2009;27:131-6.
2. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010;7:277-85.
3. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27:612-24.
4. Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 2009;100:1369-72.
5. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-70.
6. Gleadle JM. Review article: How cells sense oxygen: lessons from and for the kidney. Nephrology (Carlton) 2009;14:86-93.
7. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, et al. VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010;221:125-38.
8. Godinot C, de Laplanche E, Hervouet E, et al. Actuality of Warburg's views in our understanding of renal cancer metabolism. J Bioenerg Biomembr 2007;39:235-41.
9. Ozcan A, Shen SS, Zhai QJ, et al. Expression of GLUT1 in primary renal tumours: morphologic and biologic implications. Am J Clin Pathol 2007;128:245-54.
10. Firth JD, Ebert BL, Ratcliffe PJ. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem 1995;270:21021-7.
11. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 2006;281:9030-7.
12. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9.
13. Xie H, Valera VA, Merino MJ, et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 2009;8:626-35.
14. Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005;8:143-53.
15. Papandreou I, Cairns RA, Fontana L, et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006;3:187-97.
16. Hervouet E, Demont J, Pecina P, et al. A new role for the von Hippel-Lindau tumour suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesis. Carcinogenesis 2005;26:531-9.
17. Park JY, Lin PY, Weiss RH. Targeting the PI3K-Akt pathway in kidney cancer. Expert Rev Anticancer Ther 2007;7:863-70.
18. Robey RB, Hay N. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 2009;19:25-31.
19. Bartrons R, Caro J. Hypoxia, glucose metabolism and the Warburg's effect. J Bioenerg Biomembr 2007;39:223-9.
20. Langbein S, Frederiks WM, zur Hausen A, et al. Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer. Int J Cancer 2008;122:2422-8.
21. Sharma SG, Nanda S, Longo S. Anti-angiogenic therapy in renal cell carcinoma. Recent Pat Anticancer Drug Discov 2010;5:77-83.
22. Spitz MR, Duphorne CM, Detry MA, et al. Dietary intake of isothiocyanates: evidence of a joint effect with glutathione S-transferase polymorphisms in lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9:1017-20.
23. Klein A, Chan AW, Caplan BU, et al. NADP+ reduction by human lymphocytes. Clin Exp Immunol 1990;82:170-3.
24. Bernstein H, Holubec H, Warneke JA, et al. Patchy field defects of apoptosis resistance and dedifferentiation in flat mucosa of colon resections from colon cancer patients. Ann Surg Oncol 2002;9:505-17.
25. Bolanos JP, Delgado-Esteban M, Herrero-Mendez A, et al. Regulation of glycolysis and pentose-phosphate pathway by nitric oxide: impact on neuronal survival. Biochim Biophys Acta 2008;1777:789-93.
26. Scott MD, Zuo L, Lubin BH, et al. NADPH, not glutathione, status modulates oxidant sensitivity in normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes. Blood 1991;77:2059-64.
27. Rezende RB, Drachenberg CB, Kumar D, et al. Differential diagnosis between monomorphic clear cell adenocarcinoma of salivary glands and renal (clear) cell carcinoma. Am J Surg Pathol 1999;23:1532-8.
28. Tun HW, Marlow LA, von Roemeling CA, et al. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One 2010;5:e10696.
29. Flavin R, Peluso S, Nguyen PL, et al. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 2010;6:551-62.
30. Horiguchi A, Asano T, Ito K, et al. Fatty acid synthase over expression is an indicator of tumour aggressiveness and poor prognosis in renal cell carcinoma. J Urol 2008;180:1137-40.
31. Horiguchi A, Asano T, Ito K, et al. Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells. J Urol 2008;180:729-36.
32. Kridel SJ, Lowther WT, Pemble CW 4th. Fatty acid synthase inhibitors: new directions for oncology. Expert Opin Investig Drugs 2007;16:1817-29.
33. Steinberg GR, Kemp BE. AMPK in Health and Disease. Physiol Rev 2009;89:1025-78.
34. Gebhard RL, Clayman RV, Prigge WF, et al. Abnormal cholesterol metabolism in renal clear cell carcinoma. J Lipid Res 1987;28:1177-84.
35. Matsumoto K, Fujiwara Y, Nagai R, et al. Expression of two isozymes of acyl-coenzyme A: cholesterol acyltransferase-1 and -2 in clear cell type renal cell carcinoma. Int J Urol 2008;15:166-70.
36. Bemlih S, Poirier MD, El Andaloussi A. Acyl-coenzyme A: cholesterol acyltransferase inhibitor Avasimibe affect survival and proliferation of glioma tumour cell lines. Cancer Biol Ther 2010;9:1025-32.
37. Pinthus JH, Kleinmann N, Tisdale B, et al. Lower plasma adiponectin levels are associated with larger tumour size and metastasis in clear-cell carcinoma of the kidney. Eur Urol 2008;54:866-73.
38. Drabkin HA, Gemmill RM. Obesity, cholesterol, and clear-cell renal cell carcinoma (RCC). Adv Cancer Res 2010;107:39-56.
39. Lawrentschuk N, Davis ID, Bolton DM, et al. Functional imaging of renal cell carcinoma. Nat Rev Urol 2010;7:258-66.
40. Adams V, Kempf W, Hassam S, et al. Determination of hexokinase isoenzyme I and II composition by RT-PCR: increased hexokinase isoenzyme II in human renal cell carcinoma. Biochem Mol Med 1995;54:53-8.
41. Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 2003;23:315-40; quiz 533.
42. Perini R, Pryma D, Divgi C. Molecular imaging of renal cell carcinoma. Urol Clin North Am 2008;35(4):605-11; vi.
43. Goldberg MA, Mayo-Smith WW, Papanicolaou N, et al. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 1997;52:510-5.
44. Ramdave S, Thomas GW, Berlangieri SU, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001;166:825-30.
45. Vercellino L, Bousquet G, Baillet G, et al. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm 2009;24:137-44.
46. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 2005;43:189-204.
47. Jennens RR, Rosenthal MA, Lindeman GJ, et al. Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome. Urol Oncol 2004;22:193-6.
48. Lyrdal D, Boijsen M, Suurkula M, et al. Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun 2009;30:519-24.
49. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122-7.
50. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a doubleblind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
51. Unwin RD, Craven RA, Harnden P, et al. Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 2003;3:1620-32.
52. Perroud B, Lee J, Valkova N, et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 2006;5:64.
53. Kind T, Tolstikov V, Fiehn O, et al. A comprehensive urinary metabolomic approach for identifying kidney cancerr. Anal Biochem 2007;363:185-95.
54. Kim K, Aronov P, Zakharkin SO, et al. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 2009;8:558-70.
55. Paillasse MR, de Medina P, Amouroux G, et al. Signaling through cholesterol esterification: a new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion. J Lipid Res 2009;50:2203-11.
56. Sharpe LJ, Brown AJ. Rapamycin down-regulates LDL-receptor expression independently of SREBP-2. Biochem Biophys Res Commun 2008;373:670-4.
57. Robb VA, Karbowniczek M, Klein-Szanto AJ, et al. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 2007;177:346-52.
58. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292:1160-4.
59. Khurana V, Caldito G, Ankem M. Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. Urology 2008;71:118-22.
60. Horiguchi A, Sumitomo M, Asakuma J, et al. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 2004;10:8648-55.
61. Woodard J, Sassano A, Hay N, et al. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res 2008;14:4640-9.
62. Hardie DG. The AMP-activated protein kinase pathway--new players upstream and downstream. J Cell Sci 2004;117:5479-87.
63. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, et al. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 2010;9:1092-9.
64. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5.
65. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-8.
66. Woodard J, Joshi S, Viollet B, et al. AMPK as a therapeutic target in renal cell carcinoma. Cancer Biol Ther 2010;10:1168-77. Epub 2010 Dec 1.
67. Maclure M, Willett W. A case-control study of diet and risk of renal adenocarcinoma. Epidemiology 1990;1:430-40.
68. Wolk A, Gridley G, Niwa S, et al. International renal cell cancer study. VII. Role of diet. Int J Cancer 1996;65:67-73.
69. Fair AM, Montgomery K. Energy balance, physical activity, and cancer risk. Methods Mol Biol 2009;472:57-88.
70. Longo VD, Fontana L. Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol Sci 2010;31:89-98.
71. Lee JE, Spiegelman D, Hunter DJ, et al. Fat, protein, and meat consumption and renal cell cancer risk: a pooled analysis of 13 prospective studies. J Natl Cancer Inst 2008;100:1695-706.
72. Lee JE, Giovannucci E, Smith-Warner SA, et al. Intakes of fruits, vegetables, vitamins A, C, and E, and carotenoids and risk of renal cell cancer. Cancer Epidemiol Biomarkers Prev 2006;15:2445-52.
73. Hu J, La Vecchia C, Negri E, et al. Dietary vitamin C, E, and carotenoid intake and risk of renal cell carcinoma. Cancer Causes Control 2009;20:1451-8.
74. Bertoia M, Albanes D, Mayne ST, et al. No association between fruit, vegetables, antioxidant nutrients and risk of renal cell carcinoma. Int J Cancer 2010;126:1504-12.
75. van Dijk BA, Schouten LJ, Oosterwijk E, et al. Carotenoid and vitamin intake, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma. Cancer Causes Control 2008;19:125-34.